Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa L Smith

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2013
Genetic heterogeneity of diffuse large B-cell lymphomaJenny Zhang, Vladimir Grubor, Cassandra L Love, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2013
Genetic heterogeneity of diffuse large B-cell lymphomaJenny Zhang, Vladimir Grubor, Cassandra L Love, et al.
Pageof 4